Literature DB >> 29301137

Associations of Fibroblast Growth Factor 23 with Markers of Inflammation and Leukocyte Transmigration in Chronic Kidney Disease.

Carin Wallquist1,2, Ladan Mansouri3, Mattias Norrbäck4, Britta Hylander1, Stefan H Jacobson5, Tobias E Larsson6, Joachim Lundahl3.   

Abstract

BACKGROUND: Patients with chronic kidney disease (CKD) show elevated levels of inflammatory markers and have an increased risk of infections as well as cardiovascular morbidity. Recent studies have implied effects of fibroblast growth factor 23 (FGF23) on inflammation in CKD. We analyzed potential correlations between levels of FGF23 with pro-inflammatory chemokines and markers of leukocyte transmigration in CKD patients.
METHODS: One hundred three patients with CKD 2-5ND and 54 healthy controls, had biochemical markers in blood and urine analyzed according to routine protocol. Pro-inflammatory cytokines were analyzed by Milliplex technique and leukocyte CD11b adhesion molecule expression was measured by flow cytometry. FGF23 levels were measured with ELISA technique. Treatment of leukocytes from healthy blood donors with FGF23 was performed in vitro and effects analyzed by flow cytometry.
RESULTS: Tumor necrosis factor-alpha, RANTES and interleukin (IL)-12 levels were significantly higher (p = 0.001, p < 0.001, and p < 0.001) in patients with CKD. Elevated FGF23 levels in the CKD group correlated to glomerular filtration rate, parathyroid hormone, urinary albumin excretion and phosphate as well as to IL-12 and RANTES. CD11b expression on resting granulocytes and monocytes, and on activated monocytes, was associated with FGF23. In vitro treatment of leukocytes with FGF23 reduced CD11b expression in resting as well as in formyl-methyinoyl-leucyl-phenylalanine-stimulated granulocytes (p = 0.03).
CONCLUSION: FGF23 levels are associated with various inflammatory markers such as pro-inflammatory cytokines and adhesion molecules on innate immune cells. However, further studies are warranted to define the direct role of FGF23 in modulation of the innate immune system in CKD.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Chronic kidney disease; Fibroblast growth factor 23; Inflammation; Innate immunity

Mesh:

Substances:

Year:  2018        PMID: 29301137     DOI: 10.1159/000485472

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  9 in total

1.  p38MAPK controls fibroblast growth factor 23 (FGF23) synthesis in UMR106-osteoblast-like cells and in IDG-SW3 osteocytes.

Authors:  F Ewendt; M Föller
Journal:  J Endocrinol Invest       Date:  2019-06-14       Impact factor: 4.256

Review 2.  Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease.

Authors:  Jodie L Babitt; Despina Sitara
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-07       Impact factor: 2.894

3.  Beyond Bone: Infectious Diseases and Immunity in Parathyroid Disorders.

Authors:  Valeria Hasenmajer; Giulia Puliani; Marianna Minnetti; Emilia Sbardella; Claudio M Mastroianni; Gabriella D'Ettorre; Andrea M Isidori; Daniele Gianfrilli
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 4.  The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia.

Authors:  Brian Czaya; Christian Faul
Journal:  Int J Mol Sci       Date:  2019-08-27       Impact factor: 5.923

Review 5.  FGF23 and Phosphate-Cardiovascular Toxins in CKD.

Authors:  Isabel Vogt; Dieter Haffner; Maren Leifheit-Nestler
Journal:  Toxins (Basel)       Date:  2019-11-06       Impact factor: 4.546

6.  Hemodiafiltration Is Associated With Reduced Inflammation and Increased Bone Formation Compared With Conventional Hemodialysis in Children: The HDF, Hearts and Heights (3H) Study.

Authors:  Dagmar-Christiane Fischer; Colette Smith; Francesca De Zan; Justine Bacchetta; Sevcan A Bakkaloglu; Ayse Agbas; Ali Anarat; Bilal Aoun; Varvara Askiti; Karolis Azukaitis; Aysun Bayazit; Ipek Kaplan Bulut; Nur Canpolat; Dagmara Borzych-Dużałka; Ali Duzova; Sandra Habbig; Saoussen Krid; Christoph Licht; Mieczyslaw Litwin; Lukasz Obrycki; Fabio Paglialonga; Anja Rahn; Bruno Ranchin; Charlotte Samaille; Mohan Shenoy; Manish D Sinha; Brankica Spasojevic; Constantinos J Stefanidis; Enrico Vidal; Alev Yilmaz; Michel Fischbach; Franz Schaefer; Claus Peter Schmitt; Rukshana Shroff
Journal:  Kidney Int Rep       Date:  2021-07-06

7.  Tumor necrosis factor-alpha is associated with mineral bone disorder and growth impairment in children with chronic kidney disease.

Authors:  Kelly Meza; Sharmi Biswas; Yuan-Shan Zhu; Anuradha Gajjar; Eduardo Perelstein; Juhi Kumar; Oleh Akchurin
Journal:  Pediatr Nephrol       Date:  2021-01-02       Impact factor: 3.651

8.  Association of vitamin D and FGF23 with serum ferritin in hypoparathyroid thalassemia: a case control study.

Authors:  Forough Saki; Azita Salehifar; Seyed Reza Kassaee; Gholamhossein Ranjbar Omrani
Journal:  BMC Nephrol       Date:  2020-11-16       Impact factor: 2.388

Review 9.  FGF23 Actions on Target Tissues-With and Without Klotho.

Authors:  Beatrice Richter; Christian Faul
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-02       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.